Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03313778 |
Title | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) |
Recruitment | Recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | Yes |
Sponsors | ModernaTX, Inc. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |